What Is Medication-Assisted Treatment?
Medication-Assisted Treatment (MAT) is an evidence-based approach that combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. The Substance Abuse and Mental Health Services Administration (SAMHSA) recognizes MAT as the gold standard for treating opioid use disorders and an important component of alcohol use disorder treatment.
Despite overwhelming scientific evidence supporting its effectiveness, MAT remains one of the most misunderstood and underutilized treatment modalities. Stigma surrounding the use of medications in recovery has historically limited access, though significant progress has been made in recent years through policy changes and public education efforts.
The three primary FDA-approved medications for opioid use disorder are buprenorphine (Suboxone, Sublocade), naltrexone (Vivitrol), and methadone. For alcohol use disorder, the approved medications include naltrexone, acamprosate (Campral), and disulfiram (Antabuse). Each works through a different mechanism and is appropriate for different clinical scenarios.
Research from the National Institute on Drug Abuse (NIDA) consistently demonstrates that MAT reduces opioid use, opioid-related overdose deaths, criminal activity, and infectious disease transmission. It also increases treatment retention and improves social functioning.
Buprenorphine: The Most Widely Prescribed MAT Medication
Buprenorphine is a partial opioid agonist that binds to opioid receptors in the brain, reducing cravings and withdrawal symptoms without producing the full euphoric effects of full agonist opioids. Most commonly prescribed as a combination product with naloxone (branded as Suboxone), buprenorphine has transformed the treatment landscape since its approval in 2002.
Clinical Evidence
Meta-analyses involving tens of thousands of patients have consistently demonstrated buprenorphine's superiority over placebo in maintaining treatment retention and reducing illicit opioid use. A landmark Cochrane Review found that patients on maintenance buprenorphine were 1.82 times more likely to remain in treatment compared to those receiving placebo.
The 2023 elimination of the X-waiver requirement — which previously restricted buprenorphine prescribing to specially certified physicians — has dramatically expanded access. Any DEA-licensed prescriber can now prescribe buprenorphine for opioid use disorder, a change that has been particularly impactful in rural and underserved communities.
Advantages
- Office-based prescribing: Can be prescribed in primary care settings, reducing barriers to access
- Ceiling effect: Partial agonist properties create a safety ceiling that reduces overdose risk
- Take-home dosing: After stabilization, patients can fill prescriptions at regular pharmacies
- Flexible dosing: Available as daily sublingual films/tablets or monthly injectable (Sublocade)
- Integration with therapy: Easily combined with cognitive-behavioral therapy and other counseling
Considerations
Buprenorphine requires careful induction timing — patients must be in mild-to-moderate withdrawal before their first dose to avoid precipitated withdrawal. Diversion remains a concern with sublingual formulations, though the monthly injectable Sublocade addresses this. Common side effects include headache, nausea, constipation, and insomnia, which typically resolve with continued treatment.
Methadone: The Longest-Standing MAT Option
Methadone, a full opioid agonist, has been used to treat opioid use disorder since the 1960s and remains one of the most extensively studied medications in all of addiction medicine. Unlike buprenorphine, methadone can only be dispensed through federally certified Opioid Treatment Programs (OTPs), which require daily in-person visits during the early phase of treatment.
Clinical Evidence
The evidence base for methadone maintenance therapy (MMT) is extraordinarily robust. Decades of randomized controlled trials, observational studies, and meta-analyses have demonstrated that MMT reduces illicit opioid use by 33-69%, decreases overdose mortality by 50-70%, reduces criminal activity by 50-60%, and substantially decreases HIV and hepatitis C transmission.
A 2023 systematic review published in The Lancet found that methadone maintenance treatment reduced all-cause mortality among individuals with opioid use disorder by approximately 50% compared to no treatment. This life-saving effect remains the strongest argument for methadone's continued role in the MAT toolkit.
Advantages
- Full agonist effect: Complete suppression of withdrawal and cravings, particularly effective for individuals with severe, long-standing opioid dependence
- No induction complications: Does not require patients to be in withdrawal before starting
- Daily supervision: Structured daily dosing provides accountability and regular clinical contact
- Long track record: Over 60 years of clinical evidence supporting effectiveness
Considerations
The requirement for daily clinic visits can be burdensome and may conflict with employment or family responsibilities. Methadone carries a meaningful risk of respiratory depression and overdose, particularly during induction or when combined with other sedating substances. Additionally, the stigma associated with methadone clinics continues to deter some individuals from seeking treatment through available programs.
Naltrexone: The Opioid Antagonist Approach
Naltrexone works through an entirely different mechanism than buprenorphine or methadone. As a full opioid antagonist, naltrexone blocks opioid receptors, preventing any opioid from producing euphoric effects. It is available as a daily oral tablet or as an extended-release monthly injectable (Vivitrol), and is also FDA-approved for alcohol use disorder.
Clinical Evidence for Opioid Use Disorder
The evidence for naltrexone in opioid use disorder is more nuanced than for agonist treatments. The landmark X:BOT trial, published in The Lancet in 2018, compared extended-release naltrexone (XR-NTX) to buprenorphine-naloxone and found comparable relapse rates once patients were successfully inducted onto their assigned medication. However, the induction barrier was significant — initiating XR-NTX required 7-14 days of opioid abstinence, and nearly 30% of patients assigned to the naltrexone group could not complete induction.
Clinical Evidence for Alcohol Use Disorder
For alcohol use disorder, naltrexone's evidence is stronger and more straightforward. Meta-analyses demonstrate that naltrexone reduces heavy drinking days by approximately 25% and increases abstinence rates by 5-10 percentage points compared to placebo. The Sinclair Method — taking naltrexone before drinking episodes to extinguish the reinforcing effects of alcohol — has shown promising results in European clinical trials, though it remains somewhat controversial in U.S. treatment circles.
Advantages
- Non-addictive: No abuse potential or diversion risk — important for certain populations and settings
- Monthly injectable: Vivitrol eliminates daily medication adherence concerns
- Dual indication: Effective for both opioid and alcohol use disorders
- No DEA scheduling: Fewer regulatory barriers to prescribing compared to agonist medications
Considerations
The induction barrier — requiring 7-14 days of complete opioid abstinence — is the most significant limitation of naltrexone for opioid use disorder. Patients who attempt to override the blockade by using high doses of opioids face serious overdose risk. Additionally, individuals who discontinue naltrexone after a period of abstinence have reduced opioid tolerance and face elevated overdose risk if they relapse.
MAT for Alcohol Use Disorder
While MAT is most commonly discussed in the context of opioid use disorder, three FDA-approved medications are available for alcohol use disorder, each targeting different neurobiological pathways.
Naltrexone for Alcohol
As discussed above, naltrexone reduces the reinforcing effects of alcohol by blocking opioid receptors involved in the reward pathway. Both oral (daily) and injectable (monthly) formulations are available. Clinical data support its use as a first-line pharmacotherapy for alcohol use disorder, particularly for individuals who report strong cravings.
Acamprosate (Campral)
Acamprosate is thought to normalize the glutamate system, which becomes dysregulated during chronic alcohol use and withdrawal. It is most effective at reducing the negative emotional and physical symptoms associated with protracted withdrawal — the internal discomfort that often drives relapse. Clinical trials demonstrate that acamprosate increases abstinence rates by approximately 10-14% compared to placebo, with its greatest benefit seen in patients who have already achieved initial abstinence.
Disulfiram (Antabuse)
Disulfiram works through aversion — it inhibits the enzyme aldehyde dehydrogenase, causing extremely unpleasant symptoms (nausea, flushing, rapid heartbeat, headache) if alcohol is consumed while taking the medication. While disulfiram does not reduce cravings, it can be highly effective for motivated individuals who benefit from an external deterrent. Supervised administration — where a partner, family member, or clinician observes daily dosing — significantly improves outcomes.
The combination of pharmacotherapy with behavioral therapies produces better outcomes than either approach alone. Current clinical guidelines recommend that all patients with moderate-to-severe alcohol use disorder be offered medication as part of a comprehensive treatment plan.
Overcoming the Stigma of MAT
Perhaps the greatest barrier to MAT utilization is persistent stigma — the belief that using medication to treat addiction is simply "replacing one drug with another." This perspective fundamentally misunderstands both the neuroscience of addiction and the mechanism of MAT medications.
Addiction involves measurable changes in brain structure and function, particularly in circuits governing reward, motivation, memory, and impulse control. MAT medications work by normalizing these disrupted brain systems, much as insulin normalizes blood sugar in diabetes or antidepressants normalize serotonin activity in depression. NIDA explicitly states that "medications used in MAT are clinically driven and tailored to meet each patient's needs."
Research consistently demonstrates that individuals on MAT have better outcomes across virtually every measured domain: treatment retention, employment, family stability, criminal justice involvement, and mortality. Withholding effective medication based on ideology rather than evidence is increasingly recognized as clinically and ethically indefensible.
The recovery community has also evolved in its understanding of MAT. Many 12-step programs and mutual aid groups now explicitly welcome members who are taking prescribed medications as part of their recovery program. This shift reflects a growing consensus that recovery is about improved functioning and quality of life, not simply the absence of all substances.
If you have questions about whether MAT might be right for you or a loved one, evidence-based guidance is available. Call (855) 428-6315 to speak confidentially with a treatment specialist who can provide personalized information about medication options.